Loss of cw-Diamminedichloroplatinum(H) Resistance in Human Ovarian Carcinoma Cells Selected for Rhodamine 123 Resistance1
نویسندگان
چکیده
Cisplatin (DDP)-resistant 2008 human ovarian carcinoma cells (C13*) have an elevated mitochondria! membrane potential that confers hypersensitivity to lipophilic cations. We have addressed whether this change was directly linked to the DDP-resistant phenotype or was a random alteration, unrelated to resistance. The elevated mitochondria! membrane potential and ensuing rhodamine 123 (Rhl23) hypersensitivity of C13* cells provided a positive selection rationale. Cells with low mitochondria! membrane potential will have a survival advantage over those with a high mitochondria! membrane potential, when exposed to Rhl23. We there fore used Rhl23 to isolate revertants (RH4) from the 12-fold DDPresistant C13* cell line that had a low mitochondrial membrane potential. RH4 cells had parental (2008) mitochondrial membrane potential levels as shown by flow cytometry analysis of Rhl23 stained cells and by tetraphenylphosphonium cation uptake. The RH4 cells lost a substantial portion of their DDP resistance such that they were only 2to 3-fold resistant to DDP. Despite this major loss of resistance, they retained a number of the phenotypic changes related to DDP resistance, observed in C13* cells. RH4 cells displayed the same DDP accumulation defect, 2-fold elevated glutathione levels and 2-fold resistance to ( d( I. as C13* cells. We conclude that although the biochemical mechanism by which an elevated mitochondrial membrane potential elicits DDP resistance is unknown, these mitochondrial changes are central to the expression of DDP resistance in C13* cells.
منابع مشابه
Mitochondrial Defects in cw-Diamminedichloroplatinum(II)-resistant Human Ovarian Carcinoma Cells1
We have been studying the membranes of cisplatin (DDP)-resistant 2008 human ovarian carcinoma cells (C13* cells) for alterations that may account for their decreased DDP accumulation. We now report that C13* cells have significant changes in their mitochondrial and plasma mem brane potentials and in their mitochondrial morphology. C13* cells accumulated 2.0 ±0.1-fold more of the membrane poten...
متن کاملcw-Diamminedichloroplatinum(II) Resistant Human l\imor Cell Lines Are Collaterally Sensitive to PtCl4(Rh-123)2: Evidence for Mitochondrial Involvement1
Three human tumor cell lines made resistant to m-diamminedichloroplatinum(II) (CDDP), SCC-25/CP, MCF-7/CP, and C13, are more sensitive to rhodamine-123 [tetrachloroplatinum(II)] |(PtCI4(Rh-123)2] than are the corresponding parental cell lines. The CDDP-resistant cells have higher intracellular concentrations of l't( I,i Uli-123). for the same exposure than do the parent cells. Each of the CDDP-...
متن کاملMitochondrial defects in cis-diamminedichloroplatinum(II)-resistant human ovarian carcinoma cells.
We have been studying the membranes of cisplatin (DDP)-resistant 2008 human ovarian carcinoma cells (C13* cells) for alterations that may account for their decreased DDP accumulation. We now report that C13* cells have significant changes in their mitochondrial and plasma membrane potentials and in their mitochondrial morphology. C13* cells accumulated 2.0 +/- 0.1-fold more of the membrane pote...
متن کاملCross-resistance to cisplatin in cells resistant to photofrin-mediated photodynamic therapy.
This study shows that a Photofrin-induced photodynamic therapy-resistant variant (RIF-8A) of a radiation-induced fibrosarcoma-1 cell line (RIF-1) is cross-resistant to cis-diamminedichloroplatinum(II) (cisplatin). This is the first study to show cross-resistance to cisplatin in photodynamic therapy-resistant variants in vitro. Resistance does not appear to be the result of elevated glutathione ...
متن کاملSRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.
Src tyrosine kinase has been found to be overexpressed in both mouse and human ovarian cancer cells as well as in human primary ovarian cancers. Furthermore, Src inhibition sensitizes ovarian cancer cells to chemotherapeutic agents such as paclitaxel and cisplatin. Interestingly, Src inhibition has also been shown to resensitize paclitaxel-resistant cells to the cytotoxic effects of paclitaxel....
متن کامل